Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Department of Structural Biology, Takeda California, 10410 Science Center Drive, San Diego, California 92121, United States.
J Med Chem. 2020 Mar 26;63(6):3215-3226. doi: 10.1021/acs.jmedchem.9b01979. Epub 2020 Mar 16.
Deoxyhypusine synthase (DHPS) utilizes spermidine and NAD as cofactors to incorporate a hypusine modification into the eukaryotic translation initiation factor 5A (eIF5A). Hypusine is essential for eIF5A activation, which, in turn, plays a key role in regulating protein translation of selected mRNA that are associated with the synthesis of oncoproteins, thereby enhancing tumor cell proliferation. Therefore, inhibition of DHPS is a promising therapeutic option for the treatment of cancer. To discover novel lead compounds that target DHPS, we conducted synthetic studies with a hit obtained via high-throughput screening. Optimization of the ring structures of the amide compound () led to bromobenzothiophene () with potent inhibitory activity against DHPS. X-ray crystallographic analysis of complexed with DHPS revealed a dramatic conformational change in DHPS, which suggests the presence of a novel allosteric site. These findings provide the basis for the development of novel therapy distinct from spermidine mimetic inhibitors.
脱亚精胺合酶(DHPS)利用亚精胺和 NAD 作为辅助因子,将亚精胺修饰掺入真核翻译起始因子 5A(eIF5A)中。亚精胺对于 eIF5A 的激活是必不可少的,而 eIF5A 的激活又在调节与癌蛋白合成相关的特定 mRNA 的蛋白质翻译中起着关键作用,从而增强肿瘤细胞的增殖。因此,抑制 DHPS 是治疗癌症的一种很有前途的治疗选择。为了发现针对 DHPS 的新型先导化合物,我们对通过高通量筛选获得的命中化合物进行了合成研究。酰胺化合物()的环结构优化得到了对 DHPS 具有强抑制活性的溴苯并噻吩()。与 DHPS 复合的 X 射线晶体结构分析揭示了 DHPS 发生了剧烈的构象变化,这表明存在一个新的变构位点。这些发现为开发不同于亚精胺模拟抑制剂的新型治疗方法提供了基础。